The application effect of percutaneous cryoablation for the stage IIIB/IV advanced non-small-cell lung cancer after the failure of chemoradiotherapy

被引:11
作者
Gao, Wei [1 ,2 ,3 ]
Guo, Zhi [1 ,2 ,3 ]
Shu, Shumiao [4 ]
Xing, Wenge [1 ,2 ,3 ]
Zhang, Weihao [1 ,2 ,3 ]
Yang, Xueling [1 ,2 ,3 ]
机构
[1] Tianjin Med Univ, Dept Intervent Therapy, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China
[2] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[4] Tianjin Univ Tradit Chinese Med, Dept Chinese Med, Tianjin, Peoples R China
基金
美国国家科学基金会;
关键词
Cryoablation; Lung cancer; Stage IIIB/IV; PALLIATIVE THORACIC RADIOTHERAPY; RADIOFREQUENCY ABLATION; FUNCTIONAL ASSESSMENT; RANDOMIZED-TRIAL; PHASE-III; CHEMOTHERAPY; THERAPY; MANAGEMENT; SAFETY;
D O I
10.1016/j.asjsur.2018.02.006
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background/Objective: A retrospective review is required to assess the application effect of percutaneous cryoablation on the stage IIIB/IV advanced non-small-cell lung cancer (NSCLC) after the failure of chemoradiotherapy. A total of twenty-two cases with stage IIIB/IV advanced NSCLC after failure of chemoradiotherapy were enrolled. Methods: Computed Tomography (CT) was used for the assessment of tumor response, and Functional Assessment of Cancer Therapy-General (FACT-G) was applied for the evaluation of quality of life. After the treatment of cryoablation, we performed a follow-up analysis. Results: The primary technique effectiveness of 100% was observed in the one month of follow-up. At three months, local tumor progression was shown in 4 of 31 lesions (13.6%). The one-year survival rate of 81.8% and progression-free rate of 27.8% were obtained. Six patients died 7, 9, 10, 12, 15 and 22 months after treatment, respectively. Decreased scores of total quality of life at one week after cryoablation (P = 0.006), but increased scores at one month after cryoablation (P = 0.024) were observed, compared with pre-cryoablation. Conclusion: Cryoablation contributes to the effective local tumor therapy for stage IIIB/IV advanced NSCLC after the failure of chemoradiotherapy. (C) 2018 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V.
引用
收藏
页码:530 / 536
页数:7
相关论文
共 50 条
  • [21] Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
    Conibear, John
    BRITISH JOURNAL OF CANCER, 2020, 123 (SUPPL 1) : 10 - 17
  • [22] Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
    Shi, Sheng-Bin
    Hu, Rong-Hang
    Qi, Jie-Lin
    Tang, Xiao-Yong
    Tian, Jing
    Li, Rui
    Chang, Chun-Xiao
    MEDICAL ONCOLOGY, 2013, 30 (02)
  • [23] Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer
    Phernambucq, Erik C. J.
    Spoelstra, Femke O. B.
    Paul, Marinus A.
    Senan, Suresh
    Melissant, Christian F.
    Postmus, Pieter E.
    Smit, Egbert F.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 36 (06) : 1052 - 1057
  • [24] The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
    Grossi, Francesco
    Rijavec, Erika
    Dal Bello, Maria Giovanna
    Defferrari, Carlotta
    Brianti, Annalisa
    Barletta, Giulia
    Genova, Carlo
    Murolo, Carmelina
    Cosso, Maurizio
    Fontanini, Gabriella
    Boldrini, Laura
    Truini, Mauro
    Pronzato, Paolo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1407 - 1412
  • [25] Chemoradiotherapy in Advanced Non Small Cell Lung Cancer
    Erraisse, M. Ait
    Abboud, F. Z.
    Hassouni, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S942 - S942
  • [26] Treatment of elderly patients with stage IV non-small-cell lung cancer
    Weiss, Jared
    Stinchcombe, Thomas E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (01) : 111 - 120
  • [27] Prognostic impact of prognostic nutritional index in advanced (stage IIIB/IV) non-small cell lung cancer patients
    Li, X. L.
    Yao, Z. H.
    Wan, Y. Y.
    Mou, X. Y.
    Ni, Y. H.
    Sun, E. L.
    Zang, D.
    Lin, D. J.
    NEOPLASMA, 2019, 66 (06) : 971 - 977
  • [28] Concomitant radiochemotherapy of advanced non-small-cell lung cancer
    Fietkau, R
    LUNG CANCER, 2001, 33 : S65 - S76
  • [29] Crizotinib in the management of advanced-stage non-small-cell lung cancer
    Loong, Herbert H.
    Mok, Kevin
    Leung, Linda K. S.
    Mok, Tony S. K.
    FUTURE ONCOLOGY, 2015, 11 (05) : 735 - 745
  • [30] Anlotinib hydrochloride consolidation after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: a truncated, randomized, multicenter, clinical study (ALTER-L029)
    Yang, Dan
    Li, Xiaomin
    Xue, Xiaoying
    Jiang, Leilei
    Shi, Anhui
    Zhao, Jun
    ANTI-CANCER DRUGS, 2024, 35 (07) : 680 - 685